Tonix Pharmaceuticals Holding Forum: Community User: StefanN19

N.i.ete

Börsenschluss endet im + . Hosen voll alle ? 🤣🤣🤣🤣🤣🤣

Ich hatte euch vor Tagen geschrieben. Das kann hier nur noch Berg ab gehen! Da waren meine Kontakte von der Bank Toilette doch gar nicht so schlecht.......... 43 Cent ist das Ziel

LuckyLuke55....... zeigst du noch Interesse?

Schon 70 tsd verlust

Und weiter geht's Berg ab

Ich denke 6 Monate halten. Dann entscheiden

Nur dauert ihre Forschung noch...

Beim Thema "Operation Warp Speed" war tonix mit am Tisch.

Warp Speed🤣

Warp Speed ist noch nicht vom Tisch 😎

Vieles wird sich im letzten Quartal abspielen

Tonix expects small animal and non-human primate data from safety studies of TNX-1800 in COVID-19 models to measure safety and the immune response to the SARS-COV-2 Spike protein in the fourth quarter of 2020. In addition, we also expect data from non-human primate studies to measure efficacy in challenge studies using SARS-COV-2 in the fourth quarter.

The second quarter was highlighted by exciting progress for our lead immunology and central nervous system product candidates,” said Seth Lederman, M.D., President and Chief Executive Officer. “We expect to have the first data from animal studies of our lead COVID-19 vaccine candidate, TNX-1800, in the fourth quarter of this year. TNX-1800 is a live attenuated vaccine based on our proprietary horsepox vector system that carries a gene encoding the Spike protein from SARS-CoV-2, the virus that causes COVID-19. We have also continued to progress the Phase 3 RELIEF study of TNX-102 SL for fibromyalgia, having reached 50% enrollment in April and then completing enrollment in July, ahead of schedule. We look forward to interim data in September and topline results from the RELIEF study by the end of this year.”

https://ir.tonixpharma.com/press-releases/detail/1222